These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 28422791)

  • 1. Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines.
    Temchura V; Überla K
    Curr Opin HIV AIDS; 2017 May; 12(3):272-277. PubMed ID: 28422791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.
    Elsayed H; Nabi G; McKinstry WJ; Khoo KK; Mak J; Salazar AM; Tenbusch M; Temchura V; Überla K
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.
    Storcksdieck genannt Bonsmann M; Niezold T; Temchura V; Pissani F; Ehrhardt K; Brown EP; Osei-Owusu NY; Hannaman D; Hengel H; Ackerman ME; Streeck H; Nabi G; Tenbusch M; Überla K
    J Immunol; 2015 Nov; 195(10):4861-72. PubMed ID: 26466954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    Bogers WMJM; Barnett SW; Oostermeijer H; Nieuwenhuis IG; Beenhakker N; Mortier D; Mooij P; Koopman G; Remarque E; Martin G; Lai RP; Dey AK; Sun Y; Burke B; Ferrari G; Montefiori D; Martin L; Davis D; Srivastava I; Heeney JL
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Particle-based delivery of the HIV envelope protein.
    Asbach B; Wagner R
    Curr Opin HIV AIDS; 2017 May; 12(3):265-271. PubMed ID: 28422790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GagPol-specific CD4⁺ T-cells increase the antibody response to Env by intrastructural help.
    Nabi G; Genannt Bonsmann MS; Tenbusch M; Gardt O; Barouch DH; Temchura V; Uberla K
    Retrovirology; 2013 Oct; 10():117. PubMed ID: 24156704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines.
    Vzorov AN; Wang L; Chen J; Wang BZ; Compans RW
    Virology; 2016 Feb; 489():141-50. PubMed ID: 26761396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.
    Lewis GK; DeVico AL; Gallo RC
    Proc Natl Acad Sci U S A; 2014 Nov; 111(44):15614-21. PubMed ID: 25349379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers.
    Lee JH; Hu JK; Georgeson E; Nakao C; Groschel B; Dileepan T; Jenkins MK; Seumois G; Vijayanand P; Schief WR; Crotty S
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33355623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germinal Center Lymphocyte Ratios and Successful HIV Vaccines.
    Gonzalez-Figueroa P; Roco JA; Vinuesa CG
    Trends Mol Med; 2017 Feb; 23(2):95-97. PubMed ID: 28089302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes.
    Rosengarten JF; Schatz S; Wolf T; Barbe S; Stitz J
    Virology; 2022 Mar; 568():41-48. PubMed ID: 35101772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
    Goepfert PA; Elizaga ML; Seaton K; Tomaras GD; Montefiori DC; Sato A; Hural J; DeRosa SC; Kalams SA; McElrath MJ; Keefer MC; Baden LR; Lama JR; Sanchez J; Mulligan MJ; Buchbinder SP; Hammer SM; Koblin BA; Pensiero M; Butler C; Moss B; Robinson HL; ;
    J Infect Dis; 2014 Jul; 210(1):99-110. PubMed ID: 24403557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.
    Sarkar S; Piepenbrink MS; Basu M; Thakar J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ
    Vaccine; 2019 Apr; 37(17):2322-2330. PubMed ID: 30926296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.